|CrossRef Text and Data Mining|
|Result of CrossRef Text and Data Mining Search is the related articles with entitled article. If you click link1 or link2 you will be able to reach the full text site of selected articles; however, some links do not show the full text immediately at now. If you click CrossRef Text and Data Mining Download icon, you will be able to get whole list of articles from literature included in CrossRef Text and Data Mining.|
|Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors|
|Sheng-Mou Hsiao, Chun-Hou Liao, Ho-Hsiung Lin, Hann-Chorng Kuo|
Int Neurourol J. 2015;19(3):171-177. Published online 2015 September 22
Duration of Antimuscarinic Administration for Treatment of Overactive Bladder Before Which One Can Assess Efficacy: An Analysis of Predictive Factors
Factors involved in the success of antimuscarinic treatment
Do gender, age or lifestyle factors affect responses to antimuscarinic treatment in overactive bladder patients?
Urodynamic verification of an overactive bladder is not a prerequisite for antimuscarinic treatment response
Comparative Efficacy and Tolerability of Antimuscarinic Agents and the Selective β3-Adrenoceptor Agonist, Mirabegron, for the Treatment of Overactive Bladder: Which is More Preferable as an Initial Treatment?
690 Can baseline characteristics of subjects with overactive bladder predict responsiveness to antimuscarinic treatment
Re: Risk Factors for the Failure of Antimuscarinic Treatment with Solifenacin in Women with Overactive Bladder
MP09-13 CLINICAL EFFICACY AND SAFETY OF FULL DOSE ANTIMUSCARINIC AGENT TREATMENT ON UNSATISFACTORY IMPROVEMENT OF SYMPTOMS AFTER LOW DOSE ANTIMUSCARINIC TREATMENT IN MALE PATIENTS WITH OVERACTIVE BLADDER: A RETROSPECTIVE MULTICENTER STUDY
Increased Serum Adipokines Implicate Chronic Inflammation in the Pathogenesis of Overactive Bladder Syndrome Refractory to Antimuscarinic Therapy
Treatment Outcome of Overactive Bladder Patients Receiving Antimuscarinic Therapy for More than One Year